CDEK
← All drugs Report issue

savolitinib

Small moleculeexperimental

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China. — Wikipedia

Clinical trial activity

30 trials · 26 clinical orgs · 0 marketing orgs

Phase 1
12
Phase 2
19
Phase 3
5
Phase 4
0

Earliest trial started Sep 6, 2017 (NCT03258515)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
Mol. weight
345.37 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06692491Phase 2Jan 1, 2025Peking University
NCT06563999Phase 2Dec 1, 2024Sun Yat-Sen University
NCT06348355Phase 1Apr 12, 2024AstraZeneca, Karolinska Institute
NCT05958849Phase 2Aug 1, 2023Chinese Academy of Medical Sciences
NCT05777278Phase 1/Phase 2 (Phase 2)Jul 26, 2023Guangzhou Medical University
NCT05911425Phase 2Jul 1, 2023Chinese Academy of Medical Sciences
NCT05888207Phase 1Jun 2, 2023AstraZeneca, Parexel
NCT05768360Phase 1Apr 25, 2023AstraZeneca, Parexel
NCT05620628Phase 2Jan 31, 2023Sungkyunkwan University
NCT05374603Phase 2Dec 30, 2022AstraZeneca, Jiao Tong University
NCT05261399Phase 3Aug 3, 2022AstraZeneca, Jiao Tong University
NCT05163249Phase 2Dec 31, 2021Guangdong Academy of Medical Sciences, Guangdong Association of Clinical Trials
NCT05015608Phase 3Nov 22, 2021Chinese Academy of Medical Sciences, Hutchison MediPharma, Jiao Tong University
NCT05043090Phase 3Oct 28, 2021AstraZeneca, Harvard University
NCT05009836Phase 3Sep 6, 2021Hutchison MediPharma, Shantou University
NCT04923945Phase 3Aug 19, 2021Hutchison MediPharma, Jiao Tong University
NCT04923932Phase 2Jul 27, 2021Chinese Academy of Medical Sciences, Hutchison MediPharma
NCT04675021Phase 1Nov 13, 2020AstraZeneca, Quotient
NCT04606771Phase 2Sep 28, 2020AstraZeneca
NCT04187456Phase 1Dec 19, 2019AstraZeneca, Parexel
Showing 20 of 30 trials
Page 1 / 2

Organizations

Research & Development (26)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit151532017
Hutchison MediPharmaFor profit6532019
ParexelFor profit6012017
Chinese Academy of Medical SciencesAcademic/Hospital4222021
Jiao Tong UniversityAcademic/Hospital4022021
Harvard UniversityAcademic/Hospital2022019
National Cancer Institute (NCI)Government2222018
Sungkyunkwan UniversityAcademic/Hospital2112019
British Columbia Cancer AgencyAcademic/Hospital1012017
Canadian Cancer Clinical Trials NetworkAcademic/Hospital1012017
Canadian Cancer Trials GroupAcademic/Hospital1112017
Duke UniversityAcademic/Hospital1012018
Guangdong Academy of Medical SciencesAcademic/Hospital1012021
Guangdong Association of Clinical TrialsAcademic/Hospital1112021
Guangzhou Medical UniversityAcademic/Hospital1112023
Hamilton Health Sciences CorporationAcademic/Hospital1012017
Karolinska InstituteAcademic/Hospital1012024
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1012019
Pediatric Brain Tumor ConsortiumAcademic/Hospital1012018
Peking UniversityAcademic/Hospital1112025
26 organizations
Page 1 / 2